Bicycle Therapeutics Ltd (BCYC)

Currency in USD
7.64
+0.18(+2.41%)
Real-time Data·
BCYC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
BCYC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.557.98
52 wk Range
6.1028.67
Key Statistics
Prev. Close
7.46
Open
7.55
Day's Range
7.55-7.98
52 wk Range
6.1-28.67
Volume
167.1K
Average Volume (3m)
285.7K
1-Year Change
-66.92%
Book Value / Share
10.7
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BCYC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
25.55
Upside
+234.36%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Bicycle Therapeutics Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Strong Sell

Bicycle Therapeutics Ltd Company Profile

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Bicycle Therapeutics Ltd SWOT Analysis


Innovative Platform
Bicycle Therapeutics' proprietary technology drives potential in oncology, with lead asset zelenectide showing promise in metastatic urothelial cancer treatment
Clinical Milestones
Explore zelenectide's impressive 45% objective response rate and favorable safety profile in recent trials, positioning it as a potential market disrupto
Financial Strength
With a robust cash position extending into 2027, Bicycle is well-equipped to fund ongoing clinical programs and capitalize on market opportunities
Analyst Outlook
Price targets range from $26 to $40, reflecting optimism about Bicycle's pipeline and technology platforms, with an average target of $33.50
Read full SWOT analysis

Compare BCYC to Peers and Sector

Metrics to compare
BCYC
Peers
Sector
Relationship
P/E Ratio
−2.7x−2.9x−0.5x
PEG Ratio
−0.09−0.070.00
Price/Book
0.7x3.5x2.6x
Price / LTM Sales
21.2x7.6x3.3x
Upside (Analyst Target)
221.7%319.3%43.4%
Fair Value Upside
Unlock9.5%7.1%Unlock

Analyst Ratings

10 Buy
3 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 25.55
(+234.36% Upside)

Earnings

Latest Release
Aug 08, 2025
EPS / Forecast
-1.14 / -0.94
Revenue / Forecast
2.92M / 9.43M
EPS Revisions
Last 90 days

BCYC Income Statement

People Also Watch

18.66
SRPT
+3.90%
158.57
CRCL
+3.69%
3.19
RLAY
-8.74%
10.255
CRMD
-5.13%

FAQ

What Stock Exchange Does Bicycle Therapeutics Trade On?

Bicycle Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Bicycle Therapeutics?

The stock symbol for Bicycle Therapeutics is "BCYC."

What Is the Bicycle Therapeutics Market Cap?

As of today, Bicycle Therapeutics market cap is 516.63M.

What Is Bicycle Therapeutics's Earnings Per Share (TTM)?

The Bicycle Therapeutics EPS (TTM) is -3.13.

When Is the Next Bicycle Therapeutics Earnings Date?

Bicycle Therapeutics will release its next earnings report on 29 Oct 2025.

From a Technical Analysis Perspective, Is BCYC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Bicycle Therapeutics Stock Split?

Bicycle Therapeutics has split 0 times.

How Many Employees Does Bicycle Therapeutics Have?

Bicycle Therapeutics has 305 employees.

What is the current trading status of Bicycle Therapeutics (BCYC)?

As of 08 Aug 2025, Bicycle Therapeutics (BCYC) is trading at a price of 7.64, with a previous close of 7.46. The stock has fluctuated within a day range of 7.55 to 7.98, while its 52-week range spans from 6.10 to 28.67.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.